Iambic Therapeutics, Inc. (IAM) Price & Analysis

14 Followers

IAM Stock Chart & Stats

18.91

Oct 15, 2026

―

Day’s Range― - ―

52-Week Range16.15 - 19.70

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

$896.35M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

BetaN/A

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding47,400,795

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Iambic Therapeutics, Inc. News

Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics today

21:21 EDT Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics (IAM) today Published first on TheFly...

21h ago

IAM

AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPO

Shares in Nvidia ($NVDA)-backed cancer-fighting biotech Iambic Therapeutics ($IAM) soared 13% on its first day of trading following...

1d ago

IAM

Iambic Therapeutics opens at $16.15, IPO priced at $16.00

Iambic Therapeutics (IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, priced...

1d ago

IAM

Iambic Therapeutics 9.375M share IPO priced at $16.00

JPMorgan, Jefferies, BofA and Citi are acting as joint book running managers for the offering. The deal priced...

2d ago

IAM

IAM FAQ

What was Iambic Therapeutics, Inc.’s price range in the past 12 months?

Iambic Therapeutics, Inc. lowest stock price was 16.15 and its highest was 19.70 in the past 12 months.

What is Iambic Therapeutics, Inc.’s market cap?

Iambic Therapeutics, Inc.’s market cap is $896.35M.

When is Iambic Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Iambic Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Iambic Therapeutics, Inc. overvalued?

According to Wall Street analysts Iambic Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Iambic Therapeutics, Inc. pay dividends?

Iambic Therapeutics, Inc. does not currently pay dividends.

What is Iambic Therapeutics, Inc.’s EPS estimate?

Iambic Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iambic Therapeutics, Inc. have?

Iambic Therapeutics, Inc. has 47,400,795 shares outstanding.

What happened to Iambic Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Iambic Therapeutics, Inc.?

Currently, no hedge funds are holding shares in IAM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.

Popular Stocks